Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome by Zis, Panagiotis & Strydom, Andre
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.freeradbiomed.2017.08.024
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Zis, P., & Strydom, A. (2017). Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome. Free
Radical Biology and Medicine. https://doi.org/10.1016/j.freeradbiomed.2017.08.024
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
Author’s Accepted Manuscript
Clinical aspects and biomarkers of Alzheimer's
disease in Down syndrome
Panagiotis Zis, Andre Strydom
PII: S0891-5849(17)30740-2
DOI: http://dx.doi.org/10.1016/j.freeradbiomed.2017.08.024
Reference: FRB13434
To appear in: Free Radical Biology and Medicine
Received date: 13 July 2017
Revised date: 28 August 2017
Accepted date: 30 August 2017
Cite this article as: Panagiotis Zis and Andre Strydom, Clinical aspects and
biomarkers of Alzheimer's disease in Down syndrome, Free Radical Biology and
Medicine, http://dx.doi.org/10.1016/j.freeradbiomed.2017.08.024
This is a PDF file of an unedited manuscript that has been accepted for
publication. As a service to our customers we are providing this early version of
the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting galley proof before it is published in its final citable form.
Please note that during the production process errors may be discovered which
could affect the content, and all legal disclaimers that apply to the journal pertain.
www.elsevier.com
  
 
 
Clinical aspects and biomarkers of Alzheimer’s disease in Down syndrome 
 
Authors 
Panagiotis Zis (1)  
 
Andre Strydom (2, 3, 4)  
 
Affiliations 
1. Academic Department of Neurosciences, Sheffield Teaching Hospitals NHS Foundation 
Trust, UK 
2. Division of Psychiatry, University College London, London, UK  
3. Department of forensic and neurodevelopmental sciences, Institute of Psychiatry, 
Psychology and Neurosciences, King’s College London, London, UK   
4. The LonDownS Consortium, London, UK 
 
 
 
 
 
 
 
 
Word count: 4,334 
References: 96 
 
Key Words 
 
Down syndrome; Alzheimer’s disease; Familial; APP mutation; biomarkers 
 
 
 
  
 
Abstract (187 words) 
 
Alzheimer‘s disease (AD) may affect in excess of 90% of individuals with Down syndrome (DS) after 
age 60, due to duplication of the APP gene in trisomy of chromosome 21, with neuropathology 
that is comparable to Sporadic AD and Familial AD (FAD). Previous literature suggested some 
unique features in clinical presentation of dementia in DS (DSd), which might be due to diagnostic 
difficulties, or represent a real difference compared to SAD or FAD. We review current knowledge 
on clinical diagnosis and presentation of dementia in DS in comparison with FAD due to APP 
mutations and APP duplication.   We suggest that the clinical presentation in DS (prominent 
memory decline and behavioral symptoms, and early development of myoclonus and seizures) are 
similar to the clinical features associated with APP mutations that is known to have an increased 
Aβ42/ Aβ40 ratio, and highlight the relative lack of vascular complications associated with cerebral 
amyloid angiopathy in DS in comparison with those rare individuals with FAD due to duplication 
APP.  We consider the biomarker evidence associated with DS and DSd with reference to Aβ 
peptide levels and oxidative stress, and suggest future directions for research to explore the 
potential mechanisms associated with the clinical presentation of DSd.  
 
 
1. Introduction 
Almost all older adults with Down syndrome (DS) have the neuropathological hallmarks of 
Alzheimer's disease (AD) at post-mortem, consisting of progressive build-up of extracellular 
amyloid- (Aβ) plaques and intraneuronal hyperphosphorylated tau [1], which can now also be 
demonstrated with in-vivo amyloid PET imaging techniques [2, 3]. As all individuals with DS over 
the age of 50 who have undergone amyloid PET imaging have been shown to have significant 
amyloid deposition, AD brain pathology is probably universal in ageing individuals with DS.  
At the gross pathological level, AD in DS is similar to the AD pathology associated with sporadic 
Alzheimer’s disease (SAD), and many types of familial Alzheimer's disease (FAD).  However, there 
are important differences in terms of genetic mechanisms between DS, SAD, and FAD.  In DS with 
trisomy of human chromosome 21, AD is believed to be related to triplication of the APP gene, 
and the basic mechanism leading to the AD pathology is lifelong overproduction of APP, which is 
associated with deposition of Aβ [4]. DS is therefore comparable to Aβ overproduction associated 
with several other FAD mutations, while reduced clearance of Aβ is implicated in SAD [5].  
  
In this review, we will summarize the clinical presentation of AD in DS before considering current 
knowledge on fluid biomarkers associated with AD in DS in order to highlight similarities and 
differences with other types of AD, particularly FAD due to APP duplication and other APP 
mutations. 
2. Epidemiology of AD in DS  
In keeping with the pathological data, dementia is exceptionally common in older adults with 
Down syndrome, though as with SAD and FAD with a time lag of several decades after the 
development of AD pathology. Clinical dementia diagnoses show a sharp age-related increase in 
prevalence (i.e. cross-sectional rates), from less than 10% by age 49 to more than 30% by age 60 
[6].  However, as dementia is now a common cause of death in people with Down syndrome [7], 
prevalence rates may underestimate overall risk and longitudinal studies show that the cumulative 
incidence for dementia in people with Down syndrome is in excess of 90% by age 65 [8]. Although 
prevalence rates may go down with age (particularly after age 60) due to increased mortality in 
older individuals with DS and dementia (DSd) [9], incidence (rate of new cases) increased steadily 
with increasing age and did not decline after age 60, from 2.5 per 100 person years in those aged 
<50 to 13.31 per 100 person years in those aged 60 and older [9].   
While age is a strong common risk factor, DSd is thus similar to FAD with a much earlier age of 
onset, several decades before the typical onset seen in SAD. In families with PSEN1 mutations, for 
example, the typically age at diagnosis is within the range 35-55 years, but cognitive symptoms 
may manifest earlier, while those with PSEN2 mutations present between 40-70 years [10]. 
Individuals with APP mutations tend to have symptom onset between 40-65 years. DSd is thus 
comparable to FAD in terms of age of onset of dementia.  
No gender differences have been found for dementia rates in older adults with DS [9, 11], but the 
average age of menopause of women with DS was younger than in the general population, and 
the age at onset of dementia was correlated with the age of menopause for those who developed 
dementia [12].   
3. Clinical diagnosis of AD in DS 
Dementia is clinically defined as a progressive brain disorder which particularly affects higher 
cortical functions such as memory, language and orientation, and which eventually leads to death 
[13].  There are challenges to diagnosing dementia in individuals with DS. These include premorbid 
intellectual impairment and functional difficulties that need to be distinguished from subsequent 
  
decline, varying baseline functioning, and limitations in speech abilities, which means the usual AD 
screening and diagnostic tools may not be suitable in DS [6, 14]. The development of dementia 
symptoms also need to be understood in the context of a typical DS cognitive phenotype, 
including impairments in executive function, memory and motor coordination [15]. Therefore, a 
diagnostic work-up needs to carefully establish the presence of cognitive deterioration that is 
typical of AD in DS, with reference to the person’s own baseline, while excluding common co-
morbidities such as depression or thyroid dysfunction which are also common causes of apparent 
decline in DS [16].  Several diagnostic systems are available to diagnose dementia. The 
International Statistical Classification of Diseases (ICD) 10 system’s criteria include decline in 
memory, together with decline in other cognitive abilities such as organization, judgement and 
information processing and decline of emotional control and social behavior such as emotional 
lability and apathy [13]. The Diagnostic and Statistical Manual (DSM) system has a similar 
definition, though does not require the presence of behavioral change in the form of decline in 
emotional control and social behavior.  The DSM-IV was found to be more inclusive than ICD-10 
when used in individuals with intellectual disability [17], but predictive validity was less good when 
used in individuals with more severe intellectual disability and sensory deficits than in the general 
population despite good inter-rater reliability [18]. Overall a clinical diagnosis of dementia 
appeared to be more reliable in individuals with DS than these standard criteria and enabled 
clinicians to diagnose more cases of individuals with DS with AD [18], suggesting that there are 
some issues when applying standard criteria in the presence of premorbid cognitive impairment. 
There are however newer versions of criteria, such as the DSM-5 neurocognitive disorder 
diagnosis, which may help to improve accuracy of diagnosis in DS [19]. Interestingly, the DSM5 and 
other newer research criteria view DS as a genetic cause of AD, which potentially allows for a 
diagnosis of probable AD even if symptoms are relatively mild.  
 
4. Presenting symptoms in DS compared to FAD and SAD 
Memory decline is viewed as the key symptom associated with AD, and the majority of individuals 
with SAD and FAD present with early impairment of episodic memory, which gradually progresses 
to involve other cognitive domains. However, there are possibly some subtle differences between 
SAD and FAD. Longitudinal studies of FAD mutation carriers showed that the earliest 
neuropsychological changes were a decline in verbal memory, which occurred approximately 3 
years before symptoms became apparent [20].  Similarly, SAD is also preceded by a relatively long 
  
prodromal stage, with an amnestic picture, such as that described in mild cognitive impairment 
[21]. Nevertheless, atypical presentations are often reported in FAD and also exist in SAD.  
Behavioral and psychiatric symptoms of dementia (BPSD) such as agitation, depression, delusions 
and hallucinations occur commonly in SAD as the disease progresses. Early BPSD may also 
occasionally be a feature of PSEN1 and PSEN2 mutations which become more prominent during 
the course of the disease [10].  
4.1 Typical DS dementia presentation 
There is ongoing debate whether there are significant differences in dementia presentation in DS  
compared to SAD or FAD. Previous studies suggested that BPSD’s may precede memory 
impairment [22] in keeping with a frontal-like syndrome [23]. Several studies have described 
BPSD’s that often precede dementia diagnosis in adults with DS [24 – 26]. Individuals with DSd 
often present with behavioral problems [27, 28], which can be divided into two types – behavioral 
excesses such as irritability, aggression or self-abusive behavior, or behavioral deficits such as 
general slowness, apathy or loss of interest and decreased social engagement; behavioral excesses 
rather than deficits may trigger referral for dementia assessment [29], suggesting that caregivers’ 
bias may influence reporting and referral for symptoms. Caregivers reported forgetfulness and 
confusion as well as 'frontal lobe'-related symptoms such as slowness in activities and speech, loss 
of interest and withdrawal, along with the emergence of emotional and behavior problems as 
common presenting symptoms of dementia [30]. More recently, Dick et al. compared the 
neuropsychological profiles of higher-functioning DS individuals with dementia to individuals with 
advanced SAD while adjusting for gender and levels of functional impairment [31]. They found 
similarities in presentation, suggesting the underlying pathology may have comparable effects on 
cognitive profiles in both DS and SAD, at least during the later stages of AD.  
Establishing the sequence of early cognitive changes in DS associated with progression during 
prodromal AD remains a challenge. However, using longitudinal studies, it has been shown that 
changes in short-term recall and explicit memory may occur several years before a dementia 
diagnosis [32, 33] and recently it has been reported that immediate memory impairment may be 
one of the earliest signs of dementia in people with DS [34]. It is not clear what proportion of DS 
individuals initially present with the typical changes in memory domains that is typical of SAD, or 
with the atypical presentations associated with some of the FAD mutation carriers. In addition, 
language-based tasks are inherently difficult for individuals with DS, given the typical DS 
premorbid cognitive profile (which includes short-term verbal memory deficits) [35]. A better 
  
understanding of the sequence of decline in the presymptomatic and early stages of DSd is 
required to identify suitable outcome measures for future clinical trials. 
4.2 Unusual clinical presentations 
Visuospatial and visuoperceptual deficits commonly occur in the later stages of both SAD and FAD. 
The posterior cortical atrophy (PCA) variant of SAD is now well-recognized, with prominent visual 
processing deficits while memory is relatively preserved until later in the disease [36]. PCA may 
resent with earlier onset and affects parietal, occipital and occipito-temporal brain regions,  
therefore have an impact on literacy, numeracy and praxis. Some studies have found increased 
neurofibrillary tangles but similar amyloid plaque density in visual areas, with fewer tangles or 
plaques in the hippocampus in PCA compared to typical SAD, possibly associated with particular 
genetic status (including APOE4) [37]. There are no data on PCA-like presentations in DS, but 
anecdotally some individuals may present with visuoperceptual difficulties including difficulty 
managing stairs or steps, being scared of sitting on chairs and having difficulty managing toiletting 
due to not being able to discriminate toilet seats from background colors [38].  
4.3 Neurological symptoms and signs 
Neurological symptoms and signs tend to be more prominent in FAD than SAD, and is also 
common in DSd. Up to half of DS dementia cases may present with neurological symptoms, such 
as seizures and incontinence, which are normally signs associated with advanced disease in SAD, 
suggesting that dementia presents atypically in DS, or reflecting the diagnostic difficulties, 
particularly in those with more severe ID [6].  In FAD, seizures seem to be reported more 
frequently and at an earlier stage in the disease than in SAD, occurring in more than a third with 
APP mutations [10]. Early myoclonus and seizures are observed in individuals with APP mutations 
and particularly those with APP duplications (table 1). 
Myoclonus and seizures are also very common in DS dementia, and have been described as the 
presenting symptom in some cases of especially in those with severe ID [11, 39 – 41]. Seizures are 
also predictive of rate of decline [42]. Indeed, seizures are so strongly associated with AD in older 
individuals with DS that the onset of seizures in older age should trigger an assessment for 
dementia [38].  Seizures are commonly myoclonic or tonic-clonic types, with an earlier picture 
characterized by myoclonic jerks on awakening, and progression to generalized tonic-clonic 
seizures. EEG may reveal generalized slowing or spike and wave pattern [43, 44].  
  
Parkinsonism and cerebellar signs do not usually become apparent until several years into the 
clinical course of SAD, but may be more strongly associated with some forms as FAD, such as 
PSEN1 and PSEN2 mutations. Cerebellar Aβ deposition is a common feature in both FAD and SAD. 
Extrapyramidal signs such as rigidity, bradykinesia and an abnormal posture and gait has also been 
described in DS dementia [40] and by end-stage, all individuals were unable to walk and 
incontinent, and almost all had seizures [8] and many had Parkinsonian features [39, 41]. 
Cerebellar ataxia may however be an overlooked sign of dementia in DS, since brains of elderly 
patients with Down syndrome have also been found to have significant cerebellar Aβ deposition  
[45].  
 
5. APP mutations and APP duplications compared to DS  
The APP gene is situated on chromosome 21, and mutations in this gene is therefore of particular 
interest in comparison with DS. The majority of pathogenic APP mutations affect the β and γ 
secretase cleavage sites of the protein, while in the case of APP duplications, there is an extra copy 
of the whole of the APP region on chromosome 21. These individuals with APP microduplications 
therefore have the same genetic mechanism for AD as in DS, while not having extra copies of most 
of the other genes on the rest of chromosome 21 and therefore do not present with features of 
DS such as intellectual impairment or congenital heart conditions [4].  
APP mutations can be classified according to their biological effect on Aβ levels (table 1). Firstly, 
mutations that increase total Aβ without changing the Aβ42/40 ratio, such as the Swedish 
mutation at APP670/671, are associated in affected individuals with prominent memory loss and a 
classic Alzheimer's disease presentation [46].  
Other APP mutations result in increased Aβ42 levels, altering the AB42/40 ratio. Of this type, the 
‘London’ APP V717I mutation has a change at the 717 codon close to the γ secretase site.  Families 
with this mutation were found to present with early impairment of episodic memory, lack of 
insight and prominent myoclonus and seizures [47]. A so-called Austrian mutation (T714I) results 
in a 11x increase in Aβ42 levels, and presented clinically with rapidly progressive and very early 
onset dementia with early memory loss, seizures, myoclonus, parkinsonism, spasticity, and 
behavioral symptoms. It was at post-mortem found to be associated with notably absent Aβ40 
from amyloid deposits in the brain, and the deposits were largely in the form of "cloudy" diffuse 
plaques with a non-neuritic cotton-wool appearance [48].  
  
Some APP mutations result in changes in Aβ aggregation. These include the ‘Dutch mutation’ 
(E693Q) with a distinct phenotype with severe cerebral amyloid angiopathy (CAA) leading to 
recurrent cerebral hemorrhage (ICH) and consequent focal neurological symptoms and signs. Most 
patients also develop dementia [49]. A neighboring mutation at position 692 (Flemish mutation) 
has also been reported to present with hemorrhages and a progressive dementia associated with 
CAA [50]. Interestingly, this mutation has been shown to inhibit aggregation, but fibril formation is 
specifically increased through interaction with gangliosides in the vascular wall, resulting in CAA 
[51]. The Iowa mutation (D694N) also promotes fibrillogenesis of Aβ with severe CAA on 
pathological investigation, widespread neurofibrillary tangles and amyloid plaques with 
particularly prominent Aβ40 deposition often resulting in ICH and hemorrhagic stroke [52].  
Duplications of the APP gene can also cause FAD with a cognitive phenotype that is similar to SAD, 
with early progressive impairment of episodic memory but with an onset age of between 39 and 
64 years [53-55]. Characteristic features include seizures (up to 57%) as well as prominent amyloid 
angiopathy (CAA) with hemorrhagic stroke occurring in a third of individuals [56]. In comparison, 
ICH and stroke appears to be rarer (3-4%) in individuals with DSd [57] despite the similar APP 
mechanism.  
At the clinical level, DSd therefore seems to present with a symptoms similar to those APP 
mutations that have an altered Aβ42/40 ratio, and unlike FAD due to APP duplication, seems to be 
somewhat protected against ICH and hemorrhagic stroke, suggesting the potential presence of a 
mechanism/s associated with chromosome 21 triplication that shifts the risk away from vascular 
complications. Such a protective mechanism might involve amyloid processing or clearance,  
vascular protective factors, a unique oxidative stress profile or immune response [56]. We next 
review biomarker evidence, with a particular focus on biomarkers that might shed light on the 
apparent difference in clinical presentation of dementia between duplication APP and trisomy 21. 
  
6. Fluid biomarkers of AD in DS (table 2) 
Biomarkers are objective measures of a biological or pathogenic process that can be used to 
estimate the risk for developing a disease, to guide clinical diagnosis, to evaluate prognosis, to 
monitor progression and/or response to therapeutic interventions [58].  Biomarkers can be found 
in different types of fluids, including blood (serum or plasma), cerebrovascular fluid (CSF), and 
urine.  
  
6.1. Peripheral fluid biomarkers 
6.1.1. Blood biomarkers 
The advantage of plasma and serum is that they are easily available and considered as relatively 
non-invasive. In AD several novel blood biomarkers have been proposed, although verification and 
validation in independent studies remains to be further established [59]. 
Amyloid-beta 
Amyloid-beta plays a central role in the pathogenesis of Alzheimer's disease (AD) and has been 
postulated as a potential biomarker for AD in the general population [60]. DS subjects show higher 
plasma Aβ42 and Aβ40 levels compared to cognitively normal subjects without trisomy 21 [61, 
62]. Although some studies found no differences comparing DS with and without dementia, an 
association between Aβ levels and neuropsychological scores in multivariable adjusted models 
was found [61, 63]. Also, demented DS subjects with longer dementia duration showed higher 
Aβ42, lower Aβ40 and a higher Aβ42/Aβ40 ratio than those with shorter dementia duration [63]. 
Two other studies comparing DSd to cognitively normal DS  found a higher Aβ42/Aβ40 ratio in DSd 
[64] and increased Aβ40 levels in DSd subjects [65], having adjusted for age and gender, that 
remained stable during a follow-up of several years. It is however difficult to draw any conclusions 
from these studies with regard to Aβ42/Aβ40 ratios in DS given the relatively weak correlation 
between these peripheral measurements and central Aβ.  
Tau 
Tau are proteins that stabilize microtubules and they are abundant in neurons of the central 
nervous system [66]. Plasma tau levels are elevated in AD but with overlapping ranges across 
diagnostic groups [67], which diminishes the utility of plasma tau as a diagnostic test [67, 68]. DS 
subjects, with or without dementia, also show higher plasma tau levels compared to age-matched 
normal subjects [69]. As tau levels correlate with cognitive scores, plasma tau levels in DS may 
indicate early neurodegeneration [69]. 
Oxidative stress markers 
Although AD is probably associated with multiple etiologies and pathophysiologic mechanisms, 
oxidative stress appears as a major part of the pathophysiologic process [70]. The anti-oxidant 
system is affected in DS, even before the onset of AD, and implicated in the cognitive phenotype 
associated with the chromosomal disorder; however the variations in the phenotype might result 
  
from several possible gene or gene product interactions [71]. Studies in young people with DS 
revealed a systemic and exacerbated oxidative stress [72], which increases with age [73].  
In DS subjects, low superoxide dismutase/glutathione peroxidase (SOD1/GPx) ratios are associated 
with worse memory ability [74] and in a longitudinal study it was shown that superoxide 
dismutase enzyme levels are associated with memory decline over time [75].  
Neopterin, an unconjugated pteridine that is secreted in large quantities by activated 
macrophages, can be used as a clinical marker of activated cellular immunity and oxidative stress 
in AD [76]. Plasma neopterin levels have been found to be higher in patients with AD in general 
[77, 78] and people with DS and AD in particular [79, 80].   
In summary, DS is associated with increased oxidative stress, which is present even in younger 
individuals, and it appears that markers of oxidative stress worsen during ageing, and with the 
development of AD in DS. Higher superoxide dismutase levels relative to glutathione peroxidase 
could protect against decline but it is not clear how this and other effects related to trisomy 21 
affect the presentation of dementia in DS, or whether it could explain apparent differences with 
individuals with FAD due to APP microduplication.  
6.1.2 Urine biomarkers 
Similarly to blood, the advantage of urine is that it is easily obtainable and non-invasive. Although 
few urine biomarkers have been studied in the general AD population (such as neural thread 
protein, a phosphoprotein associated with the neurofibrillary tangles of AD [81, 82], no specific 
studies of urine biomarker of AD in DS have been conducted to date other than urine markers of 
oxidative stress or activated cellular immunity. 
Isoprostane 8,12-iso-iPF2alpha 
Isoprostane 8,12-iso-iPF2alpha are chemically stable, sensitive and specific biomarkers of lipid 
peroxidation in vivo [83] and have been shown to be increased in Alzheimer’s disease [84], and 
may mediate the neuronal response to oxidative stress [85]. In a longitudinal study in subjects 
with DS, it was shown that change in iPF2alpha levels over time may have potential as a biomarker 
for memory decline in DS and potentially also help to track progression of MCI to AD [86]. 
Neopterin 
  
Similarly to the findings in plasma neopterin levels described above, urine neopterin might also 
have a potential as a biomarker of AD in DS. In a longitudinal study involving individuals with DS it 
was shown that neopterin/creatinine levels correlated with cognitive performance over time [87].  
 
6.2. CSF biomarkers 
A major advantage of CSF biomarkers is the fact that proteins or peptides that may be directly 
reflective of brain specific activities as well as disease pathology would most likely diffuse into CSF 
rather than into any other bodily fluid [88]. However, CSF is not easily available and collection is 
invasive through lumbar puncture.  As a result, few CSF studies in DS have been conducted, with 
very small numbers of participants [89]. However, in a recent systematic review and meta-analysis 
of biomarkers for the diagnosis of Alzheimer’s disease in the general population it was clearly 
shown that the core CSF biomarkers of neurodegeneration (amyloid-beta, P-tau and and T-tau) 
are strongly associated with AD mild cognitive impairment and due to their consistency CSF 
biomarkers should be used in clinical practice and clinical research [90]. In particular, in AD 
patients, T-tau is on average 2.5 times higher in CSF compared to controls, P-tau is almost 2 times 
higher in CSF compared to controls, when Aβ42 is almost 2 times lower in CSF compared to 
controls [90].  
Amyloid-beta 
CSF Aβ42 levels are lower in DS compared to non-DS control subjects and correlate negatively with 
age in the DS population [91]. In early childhood, Aβ levels tend to increase in DS, followed by a 
gradual decrease (reduced clearance from the brain) once the deposition of Aβ42 into plaques 
augments, similar to the pattern also observed in SAD and FAD [92]. Well-designed longitudinal 
data from larger studies to track change over time, and to compare CSF amyloid-beta levels 
between demented DS patients and non-demented DS, and to make comparisons with individuals 
with APP mutations or duplication APP are not yet available. 
Tau 
CSF tau levels do not differ between DS and control subjects but appear to correlate positively 
with age in DS individuals [91]. Well-designed large studies comparing CSF tau levels between 
demented DS patients and non-demented DS are not yet available, and it is thus unknown how 
changes in CSF tau levels relate to the development of dementia, or whether it might help to 
distinguish DS individuals with and without AD. 
  
Presenilin-1 
Presenelin-1 is one of the core proteins in the gamma sectretase complex, involved in APP 
processing. CSF presenilin-1 shows an age-dependent increase in cognitively normal controls [93]. 
However, the total levels of CSF presenilin-1 increased in subjects with autosomal dominant AD 
that carried PSEN1 mutations but also in DS individuals (ten demented and ten non-demented DS), 
compared with age-matched controls, even prior to the appearance of symptoms of dementia 
[93]. The implications of this finding are not clear, but CSF presenilin-1 appears to have potential 
as an early biomarker for AD in DS. 
Oxidative stress markers 
Studies involving oxidative stress markers in CSF have only been conducted in small studies of non-
DS patients with MCI. Such patients present with higher isoprostane 8, 12-iso-iPF2alpha 
(iPF2alpha) levels in CSF compared to cognitively normal elderly subjects [94]. This finding 
suggests that increased brain oxidative damage precedes the onset of symptomatic dementia and 
that measurement of this isoprostane may identify a subgroup of patients with MCI with increased 
lipid peroxidation who are at increased risk to progress to symptomatic AD [94]. A well-designed 
large study comparing CSF iPF2alpha levels between demented DS patients and non-demented DS 
is not yet available. 
7. Conclusions and future directions 
The 40-amino-acid peptide Aβ (Aβ 40) is more soluble than the longer Aβ 42 peptide and tends to 
be the major form of Aβ in the artery walls in CAA, while Aβ 42 is more prominent in plaques. In 
mutations where Aβ 42 is increased, such as the Indiana and London APP mutations, vascular 
amyloid seems to be a less prominent feature than parenchymal plaques. In contrast, if a low Aβ 
42/40 ratio is present, and in those mutations that result in altered fibril formation, CAA is 
promoted. The clinical presentation of AD in DS, with cognitive decline and worsening memory 
impairment in combination with behavioral changes, myoclonus and seizures, are comparable to 
APP mutations that result in increased Aβ42 levels relative to Aβ40 (and possibly other smaller Aβ 
peptides). Furthermore, in DS there is some evidence for a degree of protection against the CAA 
and ICH phenotypes usually associated with APP duplication, although a moderate degree of CAA 
and microbleeds have been demonstrated in DS neuropathological studies.  
Though peripheral fluid biomarkers are more accessible, CSF biomarkers, similarly to their role in 
AD in the general population, probably have better potential in predicting AD or monitoring 
  
cognitive function in DS, and also need to be used to make comparisons with FAD, particularly the 
different forms of APP mutations and APP duplication. More studies including CSF biomarkers are 
needed in DS. 
The underlying mechanism for the typical presentation of DSd is not clear. However, Amyloid 
Protein Precursor (APP) is processed in the endo-lysosomal compartment, and modifications 
within these pathways may therefore contribute to changes in Aβ concentrations involved in the 
onset of AD. The endo-lysosomal compartment is morphologically different in DS peripheral cells 
compared to euploid cells [95], and enlarged endosomes have been described in neuronal cells 
from post-mortem brains of individuals with SAD and DS [96].  The implications of these 
differences in terms of amyloid processing and Aβ peptides need to be further explored, as well as 
to identify the underlying mechanisms.  
 
Finally, markers of oxidative stress have potential as biomarkers of cognitive function in DS 
populations. However, more longitudinal and case-controlled studies are needed to confirm the 
exact role of oxidative stress in pathogenesis of AD in DS, as well as its role in the clinical 
presentation of dementia in DS. 
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Table 1: Comparison of Alzheimer’s disease clinical phenotypes between Down syndrome, 
Duplication APP, and APP mutation types.  
 Biological effect  Memory/ 
cognitive 
decline  
Behavioural/ 
emotional/ 
personality 
changes 
Myoclonus/ 
seizures 
Intra-
cerebral 
haemorrhage/ 
stroke  
AD-type APP 
mutations  e.g. 
Swedish 
mutation – 
KM670/671NL 
London  
Mutation  - 
V717I 
 
 
Increased total Aβ 
Unchanged 
Aβ42/40 
 
Increased total 
Aβ42 
Increased  
Aβ42/40 ratio 
 
 
 
Prominent 
 
 
Prominent  
 
 
Uncertain/rare 
 
 
Relatively 
prominent 
 
 
Late stages 
 
 
Prominent    
 
 
Absent/Rare 
 
 
Absent/Rare   
  
CAA-type 
APP 
mutations  
e.g. Dutch 
mutation 
E693Q;  
Italian 
mutation 
E693K 
 
 
Altered APP 
processing, 
increased Aβ 
aggregation 
 
Reduced Aβ42/40 
ratio  
 
 
Late stages 
 
 
Absent / Rare  
 
 
Uncertain  
 
 
Prominent 
Duplication 
APP CNVs  
APP 
overproduction,  
Aβ Subspecies 
ratios unknown 
Prominent Uncertain/ 
rare 
Prominent  Prominent  
Down 
syndrome  
APP 
overproduction, 
Aβ  Subspecies 
ratio unknown  
Prominent  Prominent  Prominent   Occasional 
stroke 
 
 
 
Table 2.  Overview of peripheral and central biomarkers of Alzheimer’s disease in Down syndrome.  
cnDS – cognitively normal Down syndrome subjects; dDS  - Down syndrome subjects with 
clinically diagnosed Alzheimer’s disease; SOD, superoxide dismutase; GPx, glutathione 
peroxidase; DS, down syndrome; AD, Alzheimer’s disease, CSF, cerebrospinal fluid.  
P
er
ip
h
er
a
l 
Type of fluid Biomarker Importance 
 
Blood 
Amyloid-beta DS vs. normal controls 
Higher Aβ42 and Aβ40 levels 
in subjects with DS [63] 
dDS vs. cnDS  
dDS subjects show increased 
Aβ42/Aβ40 ratio and 
increased Aβ40 levels [64, 65] 
 
Tau DS vs. normal controls 
Higher plasma tau in DS  
dDS vs. cnDS  
Tau decreases in dDS, 
possibly due to burnout 
phenomenon during long-term 
neurodegeneration [69] 
 
Oxidative stress markers 
- SOD1/GPx 
- SOD levels 
- Neopterin 
 
DS vs. controls 
Exacerbated oxidative stress 
in DS, which increases with 
age [72, 73]. 
dDS vs. cnDS  
Increased oxidative stress is 
associated with cognitive 
decline over time [75]. 
  
 
 
Urine 
Oxidative stress markers 
- Isoprostane 8,12-iso-iPF2alpha 
- Neopterin 
 
 
DS vs. controls 
Subjects with DS show 
exacerbated oxidative stress 
[86, 87].  
dDS vs. cnDS  
Increased oxidative stress is 
associated with cognitive 
decline over time [86]. 
 
C
en
tr
a
l 
 
 
 
CSF 
Amyloid-beta DS vs. normal controls 
Lower CSF Aβ42 levels in DS 
subjects, and decrease with 
age.   
dDS vs. cnDS  
Whether CSF Aβ42 levels 
correlate with cognitive 
decline or dementia remains 
to be confirmed. 
 
Tau DS vs. normal controls 
CSF tau levels increase with 
age in DS subjects. 
dDS vs. cnDS  
Whether tau levels correlate 
with cognitive decline or 
dementia remains to be 
confirmed.  
 
Presenilin-1 DS vs. normal controls 
CSF presenilin-1 is increased 
in DS subjects. 
dDS vs. cnDS  
Whether CSF presenilin-1  
levels correlate with cognitive 
decline or dementia remains 
to be confirmed. 
 
Oxidative stress markers 
- Isoprostane 8,12-iso-iPF2alpha 
 
No studies have included DS 
subjects yet. In normal 
controls, increased brain 
oxidative damage precedes 
the onset of symptomatic 
dementia; may help to 
identify a subgroup of 
patients with MCI with 
increased lipid peroxidation 
at increased risk to progress 
to symptomatic AD [94]. 
 
  
 
 
Highlights: 
 Alzheimer’s disease (AD) in Down syndrome (DS) presents with memory and cognitive 
decline, behavioural symptoms, myoclonus/seizures 
 In comparison with Familial AD due to duplication APP, vascular complications such as 
stroke is rare   
 More CSF biomarker studies are needed to explore differences in biological effects of APP 
mutations, duplication APP, and DS   
 
 
 
 
 
 
 
 
  
 
 
   
 
 
 
 
 
 
CAA-type 
APP 
mutations 
AD-type 
APP 
mutations 
Duplication 
APP 
Down 
syndrome 
CAA-type 
APP 
mutations 
AD-type 
APP 
mutations 
Duplication 
APP 
Down 
syndrome 
